

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

As of December 23, 2025

SUNDAY, MAY 3, 2026

15:00 *Welcome Coffee & Registration*

15:30 – 16:55 SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION I)

Chairs: **Jose Ángel Aibar**, *Madrid, Spain*
Emilio Perucca, *Melbourne, Australia*

15.30 **OPENING STATEMENTS**

15.40 THE NEUROBIOLOGY OF COMORBIDITIES IN DRAVET SYNDROME
Moran Rubinstein, *Tel-Aviv, Israel*

16.05 ADDRESSING GAPS IN GENETIC TESTING FOR DRAVET SYNDROME
Andreas Brunklaus, *Glasgow, UK*

16.30 UNDERSTANDING DISEASE MODIFICATION AND SYMPTOMATIC TREATMENTS FOR DRAVET SYNDROME
Simona Giorgi, *Elche, Spain*

16:55 *Coffee Break*

17:15 – 18:30 SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION II)


Chairs: **Jose Ángel Aibar**, *Madrid, Spain*
Torbjörn Tomson, *Stockholm, Sweden*

17.15 OUTCOME MEASURES: "SEIZURES AND NON-SEIZURES" IN CLINICAL TRIALS OF TREATMENTS FOR DEEs
Elaine Wirrell, *Rochester, USA*

17.40 THE IMPORTANCE OF MULTIDISCIPLINARY MANAGEMENT IN DEEs
Stéphane Auvin, *Paris, France*

18.05 PATIENT-CENTERED HEALTHCARE: THE POWER OF PATIENT ADVOCACY
José Ángel Aibar, *Madrid, Spain*

18.30 **CLOSING REMARKS**



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026

08:15 – 08:30 OPENING SESSION

ORGANIZING COMMITTEE REMARKS AND GREETINGS

Meir Bialer, *Organizing Committee, Jerusalem, Israel*

GREETINGS

Emilio Perucca, *Organizing Committee and ILAE Past-President, Melbourne, Australia*

08:30 – 10:30 Session 1: PRECLINICAL MODELS OF DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs): FROM SYMPTOMATIC TREATMENT TO DISEASE-MODIFYING AND PREVENTIVE STRATEGIES

Chairs: **Heidrun Potschka**, *Munich, Germany*
Gabriele Lignani, *London, UK*

08:30 FACE AND PREDICTIVE VALIDITY OF DEE MODELS: BASIS FOR ROBUST ASSESSMENT OF ANTISEIZURE EFFECTS
Heidrun Potschka, *Munich, Germany*

08:50 Discussion

09:00 IT'S NOT ALL ABOUT SEIZURES: ASSESSMENT OF EFFECTS ON NON-SEIZURE SYMPTOMS IN DEE MODELS **Moran Rubinstein**, *Tel-Aviv, Israel*

09:20 Discussion


09:30 PRECISION MEDICINE APPROACHES FOR DEEs: TESTING STRATEGIES CONSIDERING SPECIES DIFFERENCES AND THE INFLUENCE OF GENETIC VARIANTS
Jack M. Parent, *Ann Arbor, USA*

09:50 Discussion

10:00 THE EARLIER – THE BETTER? - ASSESSMENT OF POSSIBLE DISEASE-MODIFYING AND PREVENTIVE STRATEGIES IN DEE MODELS
Gabriele Lignani, *London, UK*

10:20 Discussion

10:30 *Coffee Break*



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

11:00 – 13:30 Session 2: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Meir Bialer**, *Jerusalem, Israel*
Emilio Perucca, *Melbourne, Australia*

- 11:00 AZETUKALNER
Chris Kenney, *Xenon Pharmaceuticals, Canada*
- 11:20 Discussion
- 11:30 BEXICASERIN (LP352)
Tolga Uz, *Lundbeck Pharmaceuticals, Denmark*
- 11:50 Discussion
- 12:00 BL-001
Louis Licamele, *Bloom Science, USA*
- 12:20 Discussion
- 12:30 Lunch Break

13:45 – 15:45 Session 3: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Piero Perucca**, *Melbourne, Australia*
Elaine Wirrell, *Rochester, USA*

- 13:45 BMB-101
Stephen Collins, *Bright Minds Biosciences, USA*
- 14:05 Discussion
- 14:15 Elsunersen
Steve Petrou, *Praxis Precision Medicines, USA*
- 14:35 Discussion
- 14:45 EPX -100
Amit Ray, *Harmony Biosciences, USA*
- 15:05 Discussion
- 15:15 ES-481
ES-Therapeutics, USA
Presented by **Terence O'Brien**, *Monash University, Australia*
- 15:35 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

15:45 Coffee Break

16:15 – 18:15 Session 4: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark**, Sandvika, Norway
Mathias Koepp, London, UK


- 16:15 ETX101
Emma James, *Encoded Therapeutics, USA*
- 16:35 Discussion
- 16:45 ION283 ASO
Berge Minassian, *University of Texas Southwestern, USA*
- 17:05 Discussion
- 17:15 Kv3.1 Targeted ASMs
Charles Large, *Autifony Therapeutics, UK*
- 17:35 Discussion
- 17:45 LRP-661 (Cannabidiol Derivatives)
Abdel-Rahman Lawendy, *London Research & Pharmaceuticals, Canada*
- 18:05 Discussion

TUESDAY, MAY 5, 2026

08:15 – 10:15 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Torbjörn Tomson**, Stockholm, Sweden
H. Steve White, Seattle, USA

- 08:15 MSCA-7136
Brad Galer, *Mosaica Medicines, USA*
- 08:35 Discussion
- 08:45 NRTX-1001
TBD Neurona Therapeutics, USA
- 09:05 Discussion
- 09:15 Opakalim (BHV-7000)
Vivian Suarez, *Biohaven Pharmaceuticals, USA*
- 09:35 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

09:45 OV329
Julia Tsai, *Ovid Therapeutics, USA*

10:05 Discussion

10:15 *Coffee Break*

10:45- 12:45 Session 6: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Meir Bialer**, *Jerusalem, Israel*
Elaine Wirrell, *Rochester, USA*

10:45 PANX1 BLOCKERS
Panntherapi, *France*
Presented by **Gill Huberfeld**, *Hôpital Fondation Adolphe de Rothschild, France*

11:05 Discussion

11:15 PrevEp-006 (SELETRACETAM)
PrevEp, *USA*
Presented by **Wolfgang Löscher**, *Hannover Medical School, Germany* and **PrevEp**, *USA*

11:35 Discussion

11:45 RADIPRODIL
Russell L. Chin, *Neurvati Neurosciences, USA*

12:05 Discussion

12:15 RAP 219
William Motley, *Rapport Therapeutics, USA*

12:35 Discussion

12:45 RELUTRIGINE
Steve Petrou, *Praxis Precision Medicines, USA*

13:05 Discussion


13:15 Lunch Break

14:30- 16:30 Session 7: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark**, *Sandvika, Norway*
Piero Perucca, *Melbourne, Australia*

14:30 SN-2000
Deborah M Kurrasch, *Stream Neuroscience Inc, USA*.

14:50 Discussion



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

- 15:00 SODIUM SELENATE
Terence O'Brien, Monash University, Australia
- 15:20 Discussion
- 15:30 SVG103
Sovargen Co, Republic of Korea
Presented by **Hing-Ho Lee**, Korea Advanced Institute of Science and Technology (KAIST)
and **Sovargen Co**, Republic of Korea
- 15:50 Discussion
- 16:00 SYNGAP 1 ASO
Yuri Maricich, CAMP4 Therapeutics, USA
- 16:20 Discussion
- 16:30 Coffee Break

17:00 – 18:30 Session 8: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Emilio Perucca**, Melbourne, Australia
H. Steve White, Seattle, USA


- 17:00 VAL-1221
Dustin Armstrong, Parasail LLC, USA
- 17:20 Discussion
- 17:30 VORMATRIGINE (PRAX-628)
Steve Petrou, Praxis Precision Medicines, USA
- 17:50 Discussion
- 18:00 ZOREVUNERSEN (STK-001)
Carolyn River, Biogen, USA
- 18:20 Discussion

WEDNESDAY, MAY 6, 2026

8:30 – 10:30 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION

Chairs: **Meir Bialer**, Jerusalem, Israel
Torbjörn Tomson, Stockholm, Sweden

- 08:30 DIAZEPAM NASAL SPRAY
Adrian L. Rabinowicz, Neurelis, USA



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA


WEDNESDAY, MAY 6, 2026, (Cont.)

- 08:50 Discussion
- 09:00 PRECLINICAL AND CLINICAL EVIDENCE IN SUPPORT OF A DISEASE MODIFYING EFFECT OF DIAZEPAM TREATMENT ON SEIZURE CLUSTERS
Presented by **Steve White**, School of Pharmacy, University of Washington, USA
- 09:20 Discussion
- 09:30 BUCCAL MIDAZOLAM
Neuraxpharm, Spain
Presented by **Federico Vigevano**, IRCCS San Raffaele and LUMSA University, Italy
- 09:50 Discussion
- 10:00 STACCATO ALPRAZOLAM
Robert Roebeling, UCB Pharma, Belgium
- 10:20 Discussion
- 10:30 Coffee Break

11:00-13:00 Session 10: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE MEDICATIONS

Chairs: **Cecilie Johannessen Landmark**, Sandvika, Norway
Emilio Perucca, Melbourne, Australia

- 11:00 BRIVARACETAM
Brian Moseley, UCB Pharma, Belgium
- 11:20 Discussion
- 11:30 CENOBAMATE
John Paul Leach, Angelini Pharma Group, Italy
- 11:50 Discussion
- 12:00 FENFLURAMINE
Brian Moseley, UCB Pharma, Belgium
- 12:20 Discussion
- 12:30 GANAXOLONE
Immedica Pharma, Sweden
Presented by **Nicola Specchio**, Bambino Gesù, Children Hospital, IRCCS, Italy
- 12:50 Discussion
- 13:00 Lunch Break



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026, (Cont.)

14:15-15:45 Session 11: PROGRESS REPORT ON RECENTLY MARKETING ANTISEIZURE DEVICES

Chairs **Mathias Koepp**, *London, UK*
Piero Perucca, *Melbourne, Australia*

- 14:15 FOCAL CORTEX STIMULATION
Precisis, Germany
Presented by **Andreas Schulze-Bonhage**, *University of Freiburg, Germany*
- 14:35 Discussion
- 14:45 RESPONSIVE NEUROSTIMULATION
Martha Morrell, *Neuropace, USA*
- 15:05 Discussion
- 15:15 VAGUS NERVE STIMULATION
Maxine Dibué-Adjei, *LivaNova, UK*
- 15:35 Discussion
- 15:45 Coffee Break

16:15 – 18:00 Session 12: DEVELOPING STATE-OF-THE-ART THERAPIES FOR DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)

Chairs: **Andreas Brunklaus**, *Glasgow, UK*
Elaine Wirrell, *Rochester, USA*

- 16:15 SELECTING POPULATIONS FOR TRIALS OF ANTISEIZURE MEDICATIONS (ASMs) FOR DEEs – SHOULD WE LUMP OR SPLIT?
Elaine Wirrell, *Rochester, USA*
- 16:35 Discussion
- 16:45 MEASURING NONSEIZURE OUTCOMES IN CLINICAL TRIALS IN DEEs
J. Helen Cross, *London, UK*
- 17:05 Discussion
- 17:15 WHAT IS MEANT BY “DISEASE MODIFYING” AND HOW DO WE PROVE THAT?
Stephane Auvin, *Paris, France*
- 17:35 Discussion
- 17:45 METHODOLOGICAL CHALLENGES IN DEVELOPING GENE THERAPIES FOR DEEs
Andreas Brunklaus, *Glasgow, UK*
- 18:05 Discussion
- 18:15 Closing Remarks

